Agrylin Related Published Studies
Well-designed clinical trials related to Agrylin (Anagrelide)
Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation. [2009.02]
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. [2005.07.07]
Well-designed clinical trials possibly related to Agrylin (Anagrelide)
Front-line therapy in polycythemia vera and essential thrombocythemia. [2012]
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. [2009.06.20]
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. [2008.01.01]
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. [2005.12.03]
What is the standard treatment in essential thrombocythemia. [2002.08]
Treatment of polycythemia vera. [1998.02]
Other research related to Agrylin (Anagrelide)
Anagrelide for the treatment of thrombocythaemia in daily clinical practice: a post-marketing observational survey on efficacy and safety performed in Germany. [2010]
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. [2009.11]
Atypical Takotsubo syndrome during anagrelide therapy. [2009.07]
[Retrospective analysis of the efficacy and tolerability of anagrelide in patients with essential thrombocytemia: Spanish registry of essential thrombocytemia] [2009.06.20]
Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide. [2009.06]
Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists. [2009.02]
Anagrelide: 20 years later. [2009.01]
[Anagrelide for treatment of patients with essential thrombocythaemia] [2008.05]
TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. [2008.04.13]
[Appearance of leg ulcers associated with intake of anagrelide] [2007.02.16]
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. [2007]
[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase] [2006.09]
Anagrelide: what was new in 2004 and 2005? [2006.06]
Effects of anagrelide on megakaryopoiesis and platelet production. [2006.06]
[Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR] [2006.05]
Anagrelide treatment in myeloproliferative disorders. [2006.04]
'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide. [2006.02]
Anagrelide: a review of its use in the management of essential thrombocythaemia. [2006]
Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. [2005.09]
A critical review of anagrelide therapy in essential thrombocythemia and related disorders. [2005.05]
Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. [2005.05]
PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. [2005.02]
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. [2005.01]
[Clinical application of anagrelide as a selective inhibitor of megakaryocyte system] [2005]
[Anagrelide in the treatment of thrombocythemia essential (ET)] [2004.12]
Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. [2004.11.15]
A long-term study of young patients with essential thrombocythemia treated with anagrelide. [2004.11]
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. [2004.10]
Anagrelide: an update on its mechanisms of action and therapeutic potential. [2004.08]
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. [2004.08]
Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. [2004.05]
Severe hypersensitivity pneumonitis associated with anagrelide. [2003.09]
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. [2003.09]
[Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia] [2002.11]
Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. [2002.06]
Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. [2002.03.01]
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. [2002.01]
[Treatment of essential thrombocythemia with anagrelide: a ten-year experience] [2002]
[Anagrelide in primary thrombocythemia] [2001.05.10]
Long-term use of anagrelide in young patients with essential thrombocythemia. [2001.02.15]
Anagrelide-induced cardiomyopathy. [2000.10]
Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. [2000.07]
Anagrelide: a novel agent for the treatment of myeloproliferative disorders. [2000.03]
[Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide] [2000]
Role of anagrelide in the treatment of thrombocytosis. [1999.10]
Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. [1999.09]
Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with Anagrelide. [1999.03]
Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. [1999.02]
Treatment of essential thrombocythemia with anagrelide. [1999.01]
[Anagrelide in control of myeloproliferative thrombocythemia: long-term experiences in 6 patients] [1998.11.14]
Anagrelide, a selective thrombocytopenic agent. [1998.10.01]
Treatment of children with anagrelide for thrombocythemia. [1998.09]
Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. [1998.08]
Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. [1998.03]
Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. [1997.07]
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. [1997]
Treatment of essential thrombocythemia with anagrelide. [1995.09]
Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. [1994.05]
[Anagrelide--new antiplatelet drug] [1994]
Therapy with Anagrelide in patients affected by essential thrombocythemia: preliminary results. [1992.07]
Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. [1992.04.15]
Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. [1992.01]
Essential thrombocythemia in a child: management with anagrelide. [1991.03]
Anagrelide: a new drug for treating thrombocytosis. [1988.05.19]
Other possibly related research studies
[Treatment of essential thrombocythemia] [2005.12]
Moyamoya syndrome in an adolescent with essential thrombocythemia: successful intracranial carotid stent placement. [2005.08]
Primary and secondary thrombocytosis in childhood. [2005.04]
Treatment paradigms in the management of myeloproliferative disorders. [2004.04]
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? [2004.04]
Essential thrombocytosis: diagnostic and treatment dilemmas. [2003.11]
Pharmacotherapy of essential thrombocythaemia: economic considerations. [2003.09]
Treatment of essential thrombocythemia in childhood. [2003.07]
Modern treatment strategies in polycythemia vera. [2003.01]
Indications for lowering platelet numbers in essential thrombocythemia. [2003.01]
Portal vein thrombosis after laparoscopy-assisted splenectomy and cholecystectomy. [2003.04]
Essential thrombocythemia (ET): moving from palliation to cure. [2002.12]
Cost-effectiveness considerations in the treatment of essential thrombocythemia. [2002.06]
Other secondary sequelae of treatments for myeloproliferative disorders. [2002.06]
Therapeutic options for essential thrombocythemia and polycythemia vera. [2002.06]
Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. [2001.08]
Hydroxyurea and periodicity in myeloproliferative disease. [2001.05]
A single institutional experience with 43 pregnancies in essential thrombocythemia. [2001.03]
Current treatment practice for essential thrombocythaemia in adults. [2001.03]
Management of patients with essential thrombocythemia: current concepts and perspectives. [2001.03]
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. [2001.03]
Thrombocytosis--report of a case. [2000.04]
[Essential thrombocythemia as a cause of headache in young woman] [2000.07]
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. [2000.01]
Treatment of polycythaemia vera and essential thrombocythaemia. [1998.12]
Regulation of megakaryocytopoiesis. [1999.09]
Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? [1999.01]
[Chronic myeloproliferative diseases] [1998.07.26]
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. [1998.03]
|
